Sarepta Therapeutics, Inc. SRPT Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s contract liabilities?
- Sarepta Therapeutics, Inc. (SRPT) reported contract liabilities of $136.35M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s contract liabilities changed year-over-year?
- Sarepta Therapeutics, Inc.'s contract liabilities decreased by 58.0% year-over-year, from $325M to $136.35M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s contract liabilities has grown at a -33.9% compound annual growth rate (CAGR), from $663.49M to $83.91M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.